{"groups":[{"description":"Patients who were unable to mobilize a minimum number of cells (CD34+ cell count \\<20 cells/ul)following 5 days of G-CSF mobilization.","id":"FG000","title":"G-CSF Plus Plerixafor"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All patients deemed to be poor mobilizers to G-CSF as a single agent, were eligible for enrollment (assuming protocol eligibility criteria were met).","recruitmentDetails":"The first patient was enrolled in April 2005 and the final patient enrolled in August 2010. The protocol was closed to accrual for approximately 3.5yrs, so the total time to protocol activation was 15 months. This was a single institution study (Duke adult stem cell transplant program)."}